tiprankstipranks
Trending News
More News >
NATCO Pharma Limited (IN:NATCOPHARM)
:NATCOPHARM
India Market

NATCO Pharma Limited (NATCOPHARM) Stock Forecast & Price Target

Compare
6 Followers
See the Price Targets and Ratings of:

NATCOPHARM Financial Forecast

NATCOPHARM Earnings Forecast

The previous quarter’s earnings for NATCOPHARM were ₹22.70.
The previous quarter’s earnings for NATCOPHARM were ₹22.70.

NATCOPHARM Sales Forecast

The previous quarter’s earnings for NATCOPHARM were ₹12.21B.
The previous quarter’s earnings for NATCOPHARM were ₹12.21B.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Dolat Capital Analyst forecast on IN:NATCOPHARM
Rashmi SanchetiDolat Capital
Not Ranked
Dolat Capital
₹1,458₹913
Sell
5.86%
Upside
Downgraded
02/14/25
Dolat Capital Downgrades Natco Pharma Ltd (NTCPH:IN) to Sell (4)Dolat Capital analyst Rashmi Shetty downgraded Natco Pharma Ltd (NTCPH:IN) from Reduce (3) to Sell (4) with a price target of INR913.00 (from INR1,458.00).
ICICI Securities Analyst forecast on IN:NATCOPHARM
Unknown AnalystICICI Securities
Not Ranked
ICICI Securities
₹1,430₹1,100
Buy
27.54%
Upside
Upgraded
02/14/25
ICICI Securities Upgrades Natco Pharma Ltd (NTCPH:IN) to Add (2)ICICI Securities analyst Vinay Bafna upgraded Natco Pharma Ltd (NTCPH:IN) from Hold (3) to Add (2) with a price target of INR1,100.00 (from INR1,430.00).
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Dolat Capital Analyst forecast on IN:NATCOPHARM
Rashmi SanchetiDolat Capital
Not Ranked
Dolat Capital
₹1,458₹913
Sell
5.86%
Upside
Downgraded
02/14/25
Dolat Capital Downgrades Natco Pharma Ltd (NTCPH:IN) to Sell (4)Dolat Capital analyst Rashmi Shetty downgraded Natco Pharma Ltd (NTCPH:IN) from Reduce (3) to Sell (4) with a price target of INR913.00 (from INR1,458.00).
ICICI Securities Analyst forecast on IN:NATCOPHARM
Unknown AnalystICICI Securities
Not Ranked
ICICI Securities
₹1,430₹1,100
Buy
27.54%
Upside
Upgraded
02/14/25
ICICI Securities Upgrades Natco Pharma Ltd (NTCPH:IN) to Add (2)ICICI Securities analyst Vinay Bafna upgraded Natco Pharma Ltd (NTCPH:IN) from Hold (3) to Add (2) with a price target of INR1,100.00 (from INR1,430.00).
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering NATCO Pharma Limited

1 Month
xxx
Success Rate
0/0 ratings generated profit
Average Return
0.00%
upgraded a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in - of your transactions generating a profit, with an average return of 0.00% per trade.
3 Months
xxx
Success Rate
0/0 ratings generated profit
Average Return
0.00%
upgraded a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in - of your transactions generating a profit, with an average return of 0.00% per trade.
1 Year
Rashmi SanchetiDolat Capital
Not Ranked
Success Rate
0/0 ratings generated profit
Average Return
0.00%
downgraded a sell rating 4 months ago
Copying Rashmi Sancheti's trades and holding each position for 1 Year would result in - of your transactions generating a profit, with an average return of 0.00% per trade.
2 Years
xxx
Success Rate
0/0 ratings generated profit
Average Return
0.00%
upgraded a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in - of your transactions generating a profit, with an average return of 0.00% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NATCOPHARM Analyst Recommendation Trends

Rating
Feb 25
May 25
Strong Buy
0
0
Buy
1
1
Hold
0
1
Sell
1
1
Strong Sell
0
0
total
2
3
In the current month, NATCOPHARM has received 1 Buy Ratings, 1 Hold Ratings, and 1 Sell Ratings. NATCOPHARM average Analyst price target in the past 3 months is 1,006.50.
Each month's total comprises the sum of three months' worth of ratings.

NATCOPHARM Stock Forecast FAQ

What is IN:NATCOPHARM’s average 12-month price target, according to analysts?
Based on analyst ratings, NATCO Pharma Limited’s 12-month average price target is 1,006.50.
    What is IN:NATCOPHARM’s upside potential, based on the analysts’ average price target?
    NATCO Pharma Limited has 16.70% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is NATCO Pharma Limited a Buy, Sell or Hold?
          NATCO Pharma Limited has a consensus rating of Hold, which is based on 0 buy ratings, 0 hold ratings and 0 sell ratings.
            What is NATCO Pharma Limited’s share price target?
            The average share price target for NATCO Pharma Limited is 1,006.50. This is based on 0 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is ₹1,100.00 ,and the lowest forecast is ₹913.00. The average share price target represents 16.70% Increase from the current price of ₹862.45.
              What do analysts say about NATCO Pharma Limited?
              NATCO Pharma Limited’s analyst rating consensus is a Hold. This is based on the ratings of 0 Wall Streets Analysts.
                How can I buy shares of NATCO Pharma Limited?
                To buy shares of IN:NATCOPHARM, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis